Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus VISIPAQUE 270.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus VISIPAQUE 270.
CONRAY 43 vs VISIPAQUE 270
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Iodinated radiocontrast agent; attenuates X-rays, providing vascular and tissue opacification.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intraarterial or intravenous administration; dose depends on procedure, age, weight, cardiac output, and clinical condition. Typical adult dose: 50-150 mL of 270 mg I/mL (50-80 mL for coronary arteriography, 30-50 mL for left ventriculography; up to 250 mL total for multiple injections).
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment, correlating with degree of kidney dysfunction.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal excretion via glomerular filtration; >95% of administered dose eliminated unchanged in urine within 24 hours. Minimal biliary or fecal excretion (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent